- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | SANUWAVE Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.09. | Sanuwave Health verstößt gegen Nasdaq-Börsenregeln: Marktkapitalisierung zu gering | 3 | Investing.com Deutsch | ||
| 25.09. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08. | Sanuwave withdraws FY2026 revenue guidance amid CMS proposal implying 97610 reimbursement of $316.59 in 2027 | 16 | Seeking Alpha | ||
| 07.08. | Sanuwave Q2 2026 slides: consumables rise as system sales slide | 1 | Investing.com | ||
| 07.08. | SANUWAVE Health GAAP EPS of -$0.08, revenue of $9.74M | 1 | Seeking Alpha | ||
| 06.08. | SANUWAVE Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | SANUWAVE Health, Inc.: Sanuwave Announces Q2 FY2026 Financial Results | 196 | GlobeNewswire (Europe) | Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026... ► Artikel lesen | |
| SANUWAVE HEALTH Aktie jetzt für 0€ handeln | |||||
| 06.08. | SANUWAVE Health, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.07. | Sanuwave sees Q2 revenue up to $9.8M | 1 | Seeking Alpha | ||
| 13.07. | Sanuwave: Q2-Umsatz übertrifft Prognose | 3 | Investing.com Deutsch | ||
| 13.07. | Sanuwave posts Q2 revenue of $9.6M-$9.8M, beating guidance | 1 | Investing.com | ||
| 13.07. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.07. | SANUWAVE Health, Inc.: Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6-$9.8 Million, Above High End of Revised Guidance | 1.074 | GlobeNewswire (Europe) | EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced... ► Artikel lesen | |
| 16.06. | SANUWAVE Health, Inc.: Sanuwave Health Updates Second Quarter 2026 Guidance | 308 | GlobeNewswire (Europe) | Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June... ► Artikel lesen | |
| 15.06. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.05. | Sanuwave forecasts Q2 revenue of $11.1M-$11.6M while maintaining $51M-$55M full-year outlook | 1 | Seeking Alpha | ||
| 13.05. | SANUWAVE Health Inc Reports Q1 2026 Results: Full Earnings Call Transcript | 3 | Benzinga.com | ||
| 13.05. | SANUWAVE Health reports mixed Q1 results; initiates Q2 and reaffirms FY26 outlook | 2 | Seeking Alpha | ||
| 12.05. | SANUWAVE Health, Inc.: Sanuwave Announces Revenues and Financial Results for Q1 FY2026 | 278 | GlobeNewswire (Europe) | Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025.... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,756 | -0,49 % | Stifel hebt Kursziel für Teladoc Health an: Kostensenkungen stärken Margen | ||
| SERNOVA BIOTHERAPEUTICS | 0,075 | +8,43 % | Sernova Biotherapeutics mit EILMELDUNG: Könnte die Aktie nach 33,3 % Plus jetzt komplett durchstarten? - Handeln Sie, bevor es zu spät ist! | ||
| CERENOME | 1,458 | -0,14 % | Cerenome completes enrollment in glioblastoma drug trial | ||
| ATOSSA THERAPEUTICS | 2,120 | +6,53 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| TANDEM DIABETES | 17,700 | 0,00 % | Tandem Diabetes Care, Inc.: Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets | Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,395 | 0,00 % | Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India | CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026Study Demonstrated 97.3% Sensitivity and 96.0% SpecificityConsistent Performance Across Three Test BatchesIntegrated Mobile... ► Artikel lesen | |
| QUIDELORTHO | 12,505 | +1,46 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,230 | 0,00 % | Oppenheimer reiterates Veru stock rating ahead of obesity trial data | ||
| LIFEWARD | 5,910 | -3,11 % | Lifeward Ltd. - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 4,170 | +1,46 % | Clover Health im Aufwind: Needham startet Coverage mit "Buy" und Kursziel von 6 Dollar | ||
| SENSEONICS | 8,500 | -1,73 % | Senseonics Holdings, Inc.: Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World's First CGM System with No On-body Component | ||
| NANO-X IMAGING | 0,303 | -0,88 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| TEMPEST THERAPEUTICS | 0,534 | +0,11 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| IMUNON | 0,805 | +7,33 % | Imunon, Inc. - S-1, General form for registration of securities |
SANUWAVE HEALTH INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 5,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SANUWAVE HEALTH INC finden Sie auf Wallstreet Online.